- Klario® is featured in The Daily Telegraph in a piece by Dr Saira Hameed, consultant endocrinologist at Imperial College Healthcare NHS Trust, on the future of diabetes care.
- The article highlights the "hypo hangover" – the brain fog and fatigue that persists after a hypoglycaemic episode even once blood glucose has normalised – as an under-recognised area of diabetes care.
- Klario® is cited as a new approach to hypo self-care, combining glucose with an alternative fuel source to support the brain during recovery.
London, UK – Flow Health Science, the London-based company behind Klario®, has been featured in The Daily Telegraph, in an article by Dr Saira Hameed exploring the advances transforming diabetes care.
In the piece, Dr Hameed highlights hypoglycaemia and its aftermath as an area of diabetes care that has historically received limited attention. While hypos have long been treated with fast-acting glucose to restore blood sugar levels, she notes that this approach does not address the "hypo hangover" – where, even after the blood glucose readings are back to normal, brain fog persists as it takes the brain a while to efficiently use glucose as a fuel.
Klario® is featured as a new approach to this problem. Dr Hameed describes it as a hypo treatment drink that 'contains glucose to raise blood sugar as well as an alternative fuel source that the brain can use' – addressing both the immediate episode and the cognitive aftermath.
"Having Klario featured in the Telegraph is a meaningful moment. It brings hypo recovery into a conversation that reaches well beyond the diabetes community." — Georgia Myers, CEO at Flow Health Science
For Flow Health Science, the feature reflects a broader recognition that current approaches to hypoglycaemia leave a real gap in patient outcomes, and that food-based innovation can help close it. It builds on a period of growing recognition for the company, following recent success at the ADA Innovation Challenge and World Food Innovation Awards.
The full article is available here. Klario® is available now at www.myklario.com.
About the Product
Klario®: A Novel Approach to Hypoglycaemia Management
Hypoglycemia represents a critical therapeutic challenge in diabetes management: people with T1D may experience 100–200 treatment-related episodes annually. Current recommended therapeutic interventions using glucose-only treatments frequently result in suboptimal outcomes, including rapid glucose fluctuations, persistent neuroglycopenic symptoms, and fear-driven non-adherence to medication. Klario, a novel multi-substrate energy formulation combining glucose with BHB, was designed to achieve more complete recovery from hypoglycemia. In line with medical guidelines, Klario delivers 15 grams of fast-acting carbs to raise blood glucose quickly, while also raising BHB levels acutely. This combination formula improves glycemic control in the immediate post-treatment period and provides rapid, sustained neuroglycopenic recovery. For more information about Klario, please visit myklario.com.
About Flow Health Science
Flow Health Science is dedicated to transforming health outcomes through trusted, clinically-proven functional foods. Grounded in advanced metabolic science, our research and pipeline targets diabetes management, fatigue, hormone imbalances, and broader metabolic dysfunction.
Media Contact: Tara Lumley, Chief Strategy & Business Officer — press@flowhealthscience.com
Source: Flow Health Science